The Fly

Ocuphire Pharma price target lowered to $20 from $26 at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Ocuphire Pharma to $20 from $26 and keeps a Buy rating on the shares. The analyst interprets the primary endpoint miss in the Phase 2 ZETA-1 trial for APX3330 as a setback, "albeit an opportunity to evaluate the future direction for the program."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on OCUP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed